Author Post: 6 Strategies to Improve Trust in Generative AI in Healthcare
Despite high consumer optimism, the adoption of gen AI in healthcare remains stagnant, with trust issues presenting a significant barrier. Here’s how that could change.
Related Articles
Fructose in food boosts cancer growth
New research shows that the liver turns fructose, a sweetener added to ultra-processed foods, into lipids that many types of cancers crave.
āSquid Gameā Season 2 Is Bloodier, More Expansive and Utterly Engaging: TV Review
In ‘Squid Game’ Season 2, Gi-hun is determined to infiltrate the game that upended his life and tear it down from the inside out.
Startup uses mushrooms for unlikely hearing aid component ā here’s how mycelium could be the solution to a growing problem
“Earplugs might not sound like a big environmental problem.”
Will an mRNA vaccine target the norovirus strain behind surging cases?
A new type of norovirus is causing a very high number of cases in countries like England, just as a large trial of an mRNA…
Impact of the timing of invasive mechanical ventilation in patients with sepsis: a multicenter cohort study – Critical Care
Background The potential adverse effects associated with invasive mechanical ventilation (MV) can lead to delayed decisions on starting MV. We aimed to explore the association…
Homeland Security launches internal AI chatbot for 19,000 staff
The tool, called DHSChat, will be available to approximately 19,000 employees at DHS headquarters and select pilot users across ten operating agencies.
We wish weād written that: STAT staffers share their favorite stories of 2024
In STAT’s “jealousy list” for 2024, STAT staffers explain what makes a selection of stories they read in other publications so compelling.
Rock ānā roll doctor Hank Wangfordās love song to the NHS
The doyen of UK country music implores us all to fight for the NHS. Itās our heart and soul, he tells Richard Hurley A longtime…
Guselkumab 100 mg Every 8 Weeks Consistently Improves Joint, Skin Through Week 24
The COSMOS trial showed guselkumab every 8 weeks improved PsA outcomes through week 48, including in patients with inadequate responses to TNF inhibitors.
